Drug Profile
Pimurutamab - Shanghai Henlius Biotech
Alternative Names: Cetuximab biobetter - Henlix Biotech; HLX 07; Recombinant humanized anti-EGFR monoclonal antibody - Shanghai Henlius BiotechLatest Information Update: 06 Dec 2023
Price :
$50
*
At a glance
- Originator Shanghai Henlius Biotech
- Class Antineoplastics; Biobetters; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Squamous cell cancer
- Phase I/II Solid tumours
Most Recent Events
- 05 Dec 2023 Efficacy and adverse events data from a phase II trial in squamous Non-small-cell Lung Cancer released by Shanghai Henlius Biotech
- 05 Dec 2023 Efficacy and adverse events data from a phase-II clinical trials in Squamous cell cancer released by Shanghai Henlius Biotech
- 06 Jun 2023 Efficacy and adverse events data from a phase II trial in Oesophageal cancer released by Shanghai Henlius Biotech